Hot Products
| Catalog No. | Information |
| CFN89340 | Bruceine E Bruceine E exhibits significant blood glucose concentration reduction activity, it might act as an insulin secretagogue. |
| CFN91973 | Bruceine J Reference standards. |
| CFN90244 | Brucine Brucine has anti-cncer activity, it can treat hepatocellular carcinoma (HCC) and inhibit the proliferation of human lung cancer cell line PC-9 mainly by blocking the cell cycle at G0/G1 via down-regulating the expression of Cyclin D1, Cyclin E. |
| CFN90316 | Brucine sulfate Brucine sulfate is a product from Strychnos nux-vomica L. |
| CFN93119 | Brusatol Brusatol, a Nrf2 inhibitor, has dual anti-hepatitis C virus and anticancer effects and can enhance the comparable effects of sorafenib. Brusatol-mediated inhibition of c-Myc/ROS signaling pathway increases HIF-1α degradation by promoting PHD activity and induces cell death in colorectal cancer under hypoxia. It inhibits the response of cultured beta-cells to pro-inflammatory cytokines in vitro. Brusatol also shows antitrypanosomal activity against trypomastigotes of Trypanosoma evansi. |
| CFN99224 | BR-Xanthone A Reference standards. |
| CFN98260 | Bryonolic acid Bryonolic acid has cytotoxic, anti-allergic, anti-inflammatory and antioxidant activities, it can reduce the inflammatory mediator NO by suppressing the expression of the inflammatory enzyme inducible nitric oxide synthase (iNOS) in LPS-activated RAW 264.7 macrophage cells. Bryonolic acid may be a promising neuroprotective agent for the treatment of cerebral ischemia disease, it can protect PC12 cells against NMDA-induced apoptosis by inhibiting Ca2+ influx and regulating gene expression in the Ca2+-CaMKII-CREB signal pathway. |
| CFN90562 | Bryonolol Reference standards. |
| CFN98519 | Buddlejasaponin IV Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation. Buddlejasaponin IV exerts cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes, it may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat. |
| CFN90709 | Buddlejasaponin IVb Buddlejasaponin IVb(200 uM) can shorten thrombin time (TT) by 20.6 %, suggests that it has hemostasis efficacy. |
